Cargando…
High-dose ivermectin in malaria and other parasitic diseases: a new step in the development of a neglected drug
We highlight the absence of high-level evidence from dose-ranging studies regarding the use of oral ivermectin in susceptible parasitic diseases. We provide published data supporting the use of a higher dosage regimen of ivermectin in malaria and difficult-to-treat head lice, and announce an ongoing...
Autores principales: | Chosidow, Olivier, Bernigaud, Charlotte, Do-Pham, Giao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
EDP Sciences
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050034/ https://www.ncbi.nlm.nih.gov/pubmed/30016258 http://dx.doi.org/10.1051/parasite/2018039 |
Ejemplares similares
-
Specific-class Skin Side-effects of Drugs Might Compromise Blinding in Randomized Controlled Trials
por: DO-PHAM, Giao, et al.
Publicado: (2023) -
Ivermectin as a potential treatment for COVID-19?
por: Chosidow, Olivier, et al.
Publicado: (2021) -
Preclinical Study of Single-Dose Moxidectin, a New Oral Treatment for Scabies: Efficacy, Safety, and Pharmacokinetics Compared to Two-Dose Ivermectin in a Porcine Model
por: Bernigaud, Charlotte, et al.
Publicado: (2016) -
The Management of Scabies in the 21st Century: Past, Advances and Potentials
por: BERNIGAUD, Charlotte, et al.
Publicado: (2020) -
Bénéfice de l’ivermectine : de la gale à la COVID-19, un exemple de sérendipité
por: Bernigaud, C., et al.
Publicado: (2020)